Sign in
Taking peopleEarly phase 1

Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis

Key facts

Who runs it
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Early phase 1
People taking part
180 people, planned
Started
22 May 2025
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • CD83-positive MSC
  • regulatory MSC
  • control solution
Record updated
25 May 2025

Who can take part

Age
0 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Age: 0-65 years old, diagnosed with sepsis
  • Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines)
  • Confirmed or suspected infection

Who cannot take part

  • Concurrent participation in other clinical trials
  • Specific medical conditions:; History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine); Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders; History of hypersensitivity or severe adverse reactions to biological products; Imminent terminal status (e.g., septic shock, life expectancy <7 days); Foreseeable risk of medical errors or disputes during hospitalization; Active drug-resistant infections; History of malignancy at screening; Pregnancy, lactation, or plans for pregnancy within the next year
  • Violation of medical ethics
  • Significant confounding factors likely to bias study outcomes
  • Poor adherence to the study protocol

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sepsis

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.

The 2 groups in the trial

  • 135 patients are infused with 1×10⁸ stem cells per sessionTreatment being tested

    Treatment: CD83-positive MSC and regulatory MSC

  • 45 patients are infused with equal volume of control solutionSham treatment, for comparison

    Treatment: control solution

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis
Criteria questions
Built from NCT06882811, who can take part
Record updated
25 May 2025